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Abstract
Background: Aberrant regulation of glycogen synthase kinase-3b (GSK-3b) has been implicated in several human
cancers; however, it has not been reported in the gastric cancer tissues to date. The present study was performed
to determine the expression status of active form of GSK-3b phosphorylated at Tyr216 (pGSK-3b) and its relationship
with other tumor-associated proteins in human gastric cancers.
Methods: Immunohistochemistry was performed on tissue array slides containing 281 human gastric carcinoma
specimens. In addition, gastric cancer cells were cultured and treated with a GSK-3b inhibitor lithium chloride (LiCl)
for immunoblot analysis.
Results: We found that pGSK-3b was expressed in 129 (46%) of 281 cases examined, and was higher in the early-
stages of pathologic tumor-node-metastasis (P < 0.001). The expression of pGSK-3b inversely correlated with
lymphatic invasion (P < 0.001) and lymph node metastasis (P < 0.001) and correlated with a longer patient survival
(P < 0.001). In addition, pGSK-3b expression positively correlated with that of p16, p21, p27, p53, APC, PTEN, MGMT,
SMAD4, or KAI1 (P < 0.05), but not with that of cyclin D1. This was confirmed by immunoblot analysis using SNU-
668 gastric cancer cells treated with LiCl.
Conclusions: GSK-3b activation was frequently observed in early-stage gastric carcinoma and was significantly
correlated with better prognosis. Thus, these findings suggest that GSK-3b activation is a useful prognostic marker
for the early-stage gastric cancer.
Background
It is thought that human cancers, including gastric car-
cinoma, develop due to the accumulation of genetic
alterations, such as oncogene activation and tumor sup-
pressor gene loss [1-3]. Thus, it is important to identify
genetic alterations that affect the behaviors of malignant
tumors.
Glycogen synthase kinase-3b (GSK-3b) is a serine/
threonine protein kinase whose activity is regulated by
site-specific phosphorylation. Complete activation of
GSK-3b generally requires phosphorylation at Tyr216
and, conversely, phosphorylation at Ser9 inhibits GSK-
3b activity [4]. Although GSK-3b was first described as
a component of the metabolic pathway for glycogen
synthase regulation, it is now known that GSK-3b is a
multi-functional kinase [5]. GSK-3b has more than 40
protein substrates and involved in a wide range of cellu-
lar processes, including differentiation, growth, motility
and apoptosis [6].
The function of GSK-3b in human cancer cells has
been most frequently evaluated in in vitro studies, which
reported opposing roles of GSK-3b. GSK-3b activation
was necessary for proliferation and survival in colorectal
cancer cells [7-10], ovarian cancer cells [11] and
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medullary thyroid cancer cells [12]. In contrast, GSK-3b
activation decreased cell proliferation of breast cancer
cells [13], prostate cancer cells [14], and colon cancer
cells [15] as well as survival of prostate cancer cells [16],
breast cancer cells [17], and colorectal cells [8]. Further-
more, in vivo xenograft studies also showed inconsistent
role of GSK-3b in tumor promotion. Inactivated GSK-
3b promoted mammary tumorigenesis [13], whereas
activated GSK-3b was essential for tumor growth of skin
cancer [18] and medullary thyroid cancer [12]. Regard-
ing the relation between GSK-3b and prognosis in
human cancers, there have been few reports. GSK-3b
expression has been correlated with a favorable outcome
in squamous cell carcinoma of the tongue [19] and
breast cancer [20]. In contrast, no significant correlation
has been noted between GSK-3b and prognosis in lung
cancer [21]. Thus, the biological significance of GSK-3b
in each cancer type needs to be elucidated.
Gastric cancer is one of the most common cancers
and the major cause of cancer related death worldwide
[22]. Thus, a molecular understanding of the genetic
factors involved in gastric cancer may contribute toward
identifying novel biomarkers. To our knowledge, there
are only 2 in vitro studies that showed the role of GSK-
3b in gastric cancer cells. Mai et al. (2006) showed that
GSK-3b inhibitors (AR-A014418, SB216763) decreased
proliferation and survival of gastric cancer cells [23]. In
contrast, Dar et al. (2009) observed that GSK-3b sup-
pression increased proliferation of gastric cancer cells
[24]. Thus, the role of GSK-3b in gastric cancer cells
still remains inconclusive. Recently, Hirakawa et al.
(2009) reported the aberrant expression of GSK-3b in
surgical gastric cancer samples [25], but they observed
only 10 samples, which made it impossible to evaluate
the clinicopatholoical significance of GSK-3b in gastric
cancer.
In the present study, we extended the previous study
to evaluate the expression status of active form of phos-
phorylated active form GSK-3b (pGSK-3b) in 281 surgi-
cally excised human gastric carcinoma tissues using
immunohistochemical tissue array analysis. Then, the
association between activated pGSK-3b and prognosis,
clinicopathological factors or cancer-related molecule
was evaluated. In addition, a gastric cancer cell line
SNU-668 was treated with a GSK-3b inhibitor lithium
chloride (LiCl) to examine the correlation between
GSK-3b and cyclin D1 expression.
Methods
Patients
The files of 281 surgically resected gastric cancer cases
examined at the Department of Pathology, Seoul
National University College of Medicine (Seoul, Korea)
from January 1 to June 30, 1995 were analyzed. Age,
gender, pathologic tumor-node-metastasis (pTNM)
stage, lymphatic invasion, lymph node metastasis, and
distant metastasis were evaluated by reviewing medical
charts and pathological records. The mean age of the
patients was 54.8 years, and 93.3% of the patients had
undergone curative resection. The cases enrolled in this
study included 217 early-stage and 64 late-stage gastric
carcinomas. According to the pTNM classification, 77
cases were in stagel, 140 in stage II, 60 in stage III, and
4 in stage IV. Patients who had received preoperative
chemotherapy or radiotherapy were excluded from the
initial case files. The clinical outcomes of the patients
were followed from the date of surgery to either the
date of death or to December 31, 2004, resulting in fol-
low-up periods ranging from 1 to 108 months (mean 35
months). Those cases lost to follow-up or those who
died of any cause other than gastric cancer were
regarded as censored data for the analysis of survival
rates.
Tissue array methods
Six array blocks containing a total of 281 tissue cores
obtained from patients with a gastric cancer were pre-
pared by Superbiochips (Seoul, Korea) as described pre-
viously [26]. Briefly, core tissue biopsies (2 mm in
diameter) were taken from individual paraffin-embedded
gastric tumors (donor blocks) and arranged in a new
recipient paraffin block (tissue array block) using a tre-
phine apparatus. As reported previously [27], the stain-
ing results of the different intratumoral areas of gastric
carcinomas in these tissue array blocks showed excellent
agreement. A core was chosen from each case for analy-
sis. We defined an adequate case as a tumor that occu-
pied 10% of the core area. Sections (4 μm thick) were
cut from each tissue array block, deparaffinized and
rehydrated. This protocol was reviewed and approved by
the Institutional Review Board of Seoul National Univer-
sity (Approval No. C-0603-162-170).
Immunohistochemistry
Immunohistochemistry used a streptavidin peroxidase
procedure after microwave antigen retrieval. Anti-phos-
pho-GSK-3bTyr216 (1:50 dilution; BD Transduction
Laboratories, San Diego, CA) was used as the primary
antibody. Other antibodies were purchased from the fol-
lowing companies: anti-p16INK4A (1:50 dilution) and
anti-retinoblastoma protein (pRb) (1:50 dilution) from
PharMingen (San Diego, CA); anti-p21Waf1/Cip1 (1:100
dilution), anti-cyclin D1 (1:500 dilution), and anti-
adenomatous polyposis coli (APC) (1:400 dilution), anti-
SMAD4 (1: 50 dilution) and anti-kangai1(KAI1) (1:200
dilution) from Santa Cruz Biotechnology (Santa Cruz,
CA); anti-O6-methylguanine DNA methyltransferase
(MGMT) (1:50 dilution) from Chemicon (Temecula,
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CA); anti-p27Kip1 (1:100 dilution) from Oncogene
(Cambridge, MA); anti-p53 (1:100 dilution) from DAKO
Corporation (Carpinteria, CA); anti-PTEN (1:50 dilu-
tion) from A.G. Scientific Inc. (San Diego, CA); anti-
fragile histidine triad (FHIT) (1:250 dilution) from
Zymed (South SanFrancisco, CA); and von Hippel Lin-
dau protein (pVHL) (Prediluted) from Neo Markers
(Fremont, CA). Visualization was performed using
3,3′-diaminobenzidine tetrahydrochloride (Sigma,
St. Louis, MO).
All immunostained sections were lightly counter-
stained with Mayer’s hematoxylin. To confirm the speci-
ficity of each antibody, isotype matched normal serum
was used as a negative control. The expression of
pGSK-3b in the nucleus and the cytoplasm of gastric
tumor cells were considered to exhibit the active form
of GSK-3b protein. For cell cycle-related proteins, can-
cer cells showing nuclear staining regardless of cytoplas-
mic staining were regarded as expressing the proteins.
The results of immunostaining were evaluated by two
pathologists (JHK and WHK), who were blinded to the
origin of the samples. The kappa value of pGSK-3b
expression was 0.816 (P < 0.001). For statistical analysis
of immunostaining, we initially scored the expression of
activated GSK-3b according to the staining intensity as
well as the proportion of immunoreactive tumor cells.
Then, to show the results clearly, we classify the results
into two categories, i.e., positive and negative. In the
present study, cases showing immunoreactivity in more
than 10% of the tumor cells with more than moderate
intensity were considered positive, because it was most
reliable cut off value in our previous experiences.
Cell culture and treatment with a GSK-3b inhibitor
A gastric cancer cell line SNU-668 obtained from the
Korean Cell Line Bank (Seoul, Korea) was cultured in
RPMI 1640 medium (Life Technologies, Inc., Grand
Island, NY) containing 10% fetal bovine serum (Life
Technologies, Inc.) and maintained in a 37°C humidi-
fied incubator containing 95% air and 5% CO2. To
inhibit the endogenous GSK-3b activity, cells were
treated with 30 mM LiCl for 48 hours and prepared
for immunoblotting.
Immunoblot analysis
Cells were lysed with 1 × Laemmli lysis buffer [2.4 M
glycerol, 0.14 M Tris (pH 6.8), 0.21 M sodium dodecyl
sulfate, 0.3 mM bromophenol blue] and then boiled for
10 minutes. Protein contents were measured using BCA
Protein Assay Reagent (Pierce, Rockford, IL). Samples
were diluted with 1 × lysis buffer containing 1.28 M b-
mercaptoethanol, and equal amounts of protein were
loaded onto 8% SDS-polyacrylamide gels. Proteins were
electrophoretically transferred to nitrocellulose
membranes, and membranes were then blocked with
7.5% nonfat dry milk in PBS-Tween-20 (0.1%, v/v) at
4°C overnight. They were then incubated with anti-
phospho-GSK-3bTyr216 (1:1000 dilution) from BD Trans-
duction Laboratories (San Diego, CA), anti-cyclin D1
(1:1000 dilution) from Cell Signaling Technology
(Beverly, MA) or anti-b-actin antibody (1:1000 dilution)
from Sigma for 3 hours, and horseradish peroxidase
conjugated anti-rabbit or anti-mouse IgG for 1 hour.
Immunoreactive proteins were visualized by enhanced
chemiluminescence (Amersham, Arlington Heights, IL).
Statistical analysis
To determine any relationship between the expressions
of pGSK-3b and clinicopathological factors or the
expressions of other proteins, either the Chi square test
or the Fisher’s exact test (two-sided) was performed.
Survival curves were estimated using the Kaplan-Meier
product-limit method, and the significance of differences
between the survival curves was determined using the
log-rank test. To determine if the expression of pGSK-
3b is an independent prognostic variable, multivariate
survival analysis was performed using the Cox propor-
tional hazard model. The results were considered statis-
tically significant when P values were less than 0.05. All
statistical analyses were conducted using SPSS version
12.0 statistical software program (SPSS, Chicago, IL).
Results
Expression of activated pGSK-3b
Figure 1 shows the representative features of immunohis-
tochemical staining of pGSK-3b (Figure 1A-C) and cyclin
D1 (Figure 1D and E). The expression of pGSK-3b was
shown in the nucleus and the cytoplasm of gastric tumor
Figure 1 Representative immunohistochemial features in
gastric cancer tissues and normal gastric tissues. Positive versus
negative examples of gastric cancer for pGSK-3b (A and B) and
cyclin D1 (D and E) (× 400). (C) A normal gastric tissue stained for
pGSK-3b (× 200). (F) Negative control treated without the primary
antibodies (× 400).
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cells (Figure 1A). In normal gastric tissue, abundant
expression of pGSK-3b was observed (Figure 1C). Immu-
nohistochemistry for cyclin D1 showed nuclear immunor-
eactivity in proliferating gastric tumor cells (Figure 1D).
Positive immunoreactivity of pGSK-3b was found in 129
(46%) of 281 surgical gastric cancer specimens (Table 1).
GSK-3b activation and clinicopathological features
Data representing the correlation between activated
GSK-3b and the clinicopathologic features of the 281
gastric cancer cases are summarized in Table 1. The
expression of pGSK-3b was more prevalent in the well-
differentiated type by WHO classification (P < 0.001)
and in the intestinal type by Lauren’s classification
(P < 0.001). In addition, the expression of pGSK-3b was
more likely to be found in the early pTNM stages
(P < 0.001). Eighty-eight percent of pGSK-3b positive
tumors were in pTNM stages I and II, while 12% were
in stages III and IV. Moreover, we found an inverse cor-
relation between the expression of pGSK-3b and lym-
phatic invasion (P < 0.001) or lymph node metastasis
(P < 0.001). No association was found between pGSK-3b
expression and age, gender, tumor location or distant
metastasis. These findings indicate that GSK-3b plays an
important role in early stages of gastric cancer.
GSK-3b activation and patient outcome
Of the 281 patients evaluated, those with pGSK-3b
expression had a significantly higher survival rate than
those without pGSK-3b expression (P < 0.001, Figure
2A). These findings indicate that pGSK-3b expression
has a significant correlation with prognosis of gastric
cancer. However, multivariate Cox regression analysis
including the pTNM stage revealed that the expression
of pGSK-3b was not an independent prognostic factor.
In addition, we analyzed the correlation between pGSK-
3b expression and patients’ prognosis in early-stage
tumors (pTNM stages I and II) and late-stage tumors
(pTNM stages III and IV) separately, and found that
pGSK-3b expression determined the survival rate in
early-stage tumors (P = 0.034, Figure 2B), but not in
late-stage tumors (P = 0.918, Figure 2C).
GSK-3b activation and cell-cycle regulators
Since cell proliferation is mainly regulated by the inter-
action of various cell cycle regulators, we investigated
the relationships between pGSK-3b and cell cycle regu-
lators. Table 2 summarizes the relationship between
activation of pGSK-3b and that of the cell cycle regula-
tors in human gastric carcinomas. The expressions of
p16, p21, p27 and p53 were statistically significantly
higher in pGSK-3b positive gastric carcinomas than in
pGSK-3b negative carcinomas (P < 0.001, P < 0.001,
P = 0.001, and P = 0.013, respectively). In contrast, the
expression of cyclin D1 or pRb showed no difference
between two groups (P = 0.202 and P = 0.208,
respectively).
GSK-3b activation and cyclin D1 expression in gastric
cancer cells in vitro
Since the present study showed that there was no corre-
lation between activated GSK-3b and cyclin D1 in clini-
cal gastric cancer samples, we confirmed these data in
the in vitro experiments using a SNU-668 gastric cancer
cell line. Immunoblotting showed that the treatment of
SNU-668 cells with LiCl decreased the expression of
Table 1 Correlation between the protein expression of
pGSK-3bTyr216 and clinicopathological factors for 281






Total (n = 281) 129 (46) 152 (54)
Age (y)
0-39 21 (46) 25 (54) 0.881
40-65 83 (47) 94 (53)
66-99 25 (43) 33 (57)
Gender
Male 94 (49) 98 (51) 0.157
Female 35 (39) 54 (61)
Locus
Antrum 63 (42) 86 (58) 0.230
Body and Cardia 66 (50) 66 (50)
WHO classification
WD 21 (78) 6 (22) < 0.001*
MD 42 (53) 37 (47)
PD 44 (37) 74 (63)
Lauren’s classification
Intestinal 63 (59) 44 (41) < 0.001*
Diffuse 62 (37) 107 (63)
Mixed 4 (80) 1 (20)
TNM stage
I 53 (69) 24 (31) < 0.001*
II 60 (43) 80 (57)
III 16 (27) 44 (73)
IV 0 (0) 4 (100)
Lymphatic invasion
Absent 104 (53) 93 (47) < 0.001*
Present 25 (30) 59 (70)
Lymph node metastasis
Absent 63 (63) 37 (37) < 0.001*
Present 66 (36) 115 (64)
Distant metastasis
Absent 124 (47) 141 (53) 0.304
Present 5 (31) 11 (69)
WD: well-differentiated adenocarcinoma; MD: moderately-differentiated
adenocarcinoma; PD: poorly-differentiated adenocarcinoma.
* Considered to be statistically significant (< 0.05).
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pGSK-3b, but not that of cyclin D1 protein (Figure 3).
These findings suggest that cyclin D1 expression is not
regulated by activated GSK-3b.
GSK-3b activation and other tumor-associated proteins
The correlations between the expression of pGSK-3b
and that of tumor suppressor gene proteins are sum-
marized in Table 3. The expression of pGSK-3b posi-
tively correlated with that of APC (P = 0.002), PTEN
(P = 0.006), MGMT (P < 0.001), SMAD4 (P = 0.001), or
KAI1 (P < 0.002). However, no association was shown
between the expression of pGSK-3b and that of pVHL
(P = 0.091) or FHIT (P = 0.387).
Discussion
The assessment of biological prognostic factors is of
clinical importance, especially for a disease with poor
outcome, such as gastric cancer. Since the biological sig-
nificance of GSK-3b in gastric carcinoma remains
unknown, we used a large scale tissue array-based
immunohistochemistry and found that the expression of
activated GSK-3b was positively associated with a good
prognosis as well as specific clinicopathologic features in
281 human gastric carcinoma samples. We believe this
is the first report on the clinical implication of activated
GSK-3b in human gastric cancer.
Figure 2 Kaplan-Meier curves for patient survival. pGSK-3b-
positive carcinomas showed a more favorable prognosis than pGSK-
3b-negative carcinomas (P < 0.001, A). Survival rate was dependent
on pGSK-3b expression in early-stage tumors (P = 0.034, B), but not
in late-stage tumors (P = 0.918, C).
Table 2 The expression of pGSK-3bTyr216 in relation to







Positive 99 (54) 84 (46) < 0.001*
Negative 24 (28) 63 (72)
p21
Positive 38 (26) 39 (74) < 0.001*
Negative 23 (12) 162 (88)
p27
Positive 23 (59) 38 (41) 0.001*
Negative 30 (3) 149 (97)
p53
Positive 56 (55) 45 (45) 0.013*
Negative 69 (40) 104 (60)
pRb
Positive 118 (45) 142 (55) 0.208
Negative 6 (67) 3 (33)
Cyclin D1
Positive 28 (53) 25 (47) 0.202
Negative 90 (43) 119 (57)
pRb: phospho-retinoblastoma protein.
* Considered to be statistically significant (< 0.05).
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In the present study, we performed immunohisto-
chemical tissue array analysis using an antibody against
activated form of GSK-3b (pGSK-3b) and found that
activated GSK-3b was expressed in 46% human gastric
cancer specimens. pGSK-3b expression was higher in
early stage tumors and was inversely associated with
lymphatic invasion and lymph node metastasis. Thus,
our results suggested that GSK-3b activation is lost dur-
ing the gastric cancer progression.
There have been a number of conflicting reports con-
cerning the prognostic implication of activated GSK-3b in
human cancers. In the present study, we found that GSK-
3b activation significantly correlated with favorable prog-
nosis in gastric cancer. Moreover, GSK-3b activation
determined the survival rate in early-stage tumors
(P = 0.034), but not in late-stage tumors. Although pTNM
staging is known to have a high prognostic power in gas-
tric cancer, it cannot predict perfectly the outcome for a
particular individual. Thus, we think that GSK-3b activa-
tion along with pTNM staging may help predict patient
outcome more accurately. Our results agreed with pre-
vious results shown in squamous cell cancer of the tongue
[19] and breast cancer [20]. However, these results do not
agree with those in lung cancer [21]. This discrepancy
may, at least in part, comes from the differential role of
GSK-3b in different cancer cell type as shown in earlier
studies [7-14,16-18,20].
Tumor growth is determined by a balance between
cell proliferation and apoptosis which are linked by cell
cycle-regulatory proteins. Although GSK-3b is known to
be a key regulator of numerous signaling pathways, mul-
tiple mechanisms are involved in the regulation of cell
cycle progression by GSK-3b [28]. The present study
analyzed the relationship between GSK-3b activation
and cell cycle regulators in gastric cancer specimens.
Among the cell cycle regulators, cyclin D1 binds cyclin-
dependent kinases (CDKs) and plays critical roles in cell
cycle progression through the G1 phase [29]. Although
both GSK-3b and cyclin D1 are known to be involved in
cell cycle regulation, their relationship in cancer cells
remains controversial. Activated GSK-3b has been
shown to inhibit cyclin D1 expression in tumor cells
including breast cancer cells [30] and squamous cancer
cells of the tongue [19]. On the contrary, GSK-3b did
not show any correlation with cyclin D1 expression in
hepatocellular carcinoma cells [31] and fibroblasts [32].
In the present study, we found that the expression of
activated GSK-3b was not correlated with that of cyclin
D1 (P = 0.202) or pRB (P = 0.208) in surgical samples.
Furthermore, treatment of gastric cancer cells with LiCl
did not change cyclin D1 expression. Thus, our findings
suggest that cyclin D1 expression in gastric cancer cells
might be regulated by signaling molecules such as Ras,
Nuclear factor-B or b-catenin rather than GSK-3b as
previously reported [31,32].
In the present study, activated GSK-3b positively cor-
related with nuclear expression of CDK inhibitors p16
(P < 0.001), p21 (P < 0.001), and p27 (P = 0.001) as well
as that of a tumor suppressor p53 (P = 0.013), but not
Figure 3 Protein expressions of pGSK-3b and cyclin D1 in SNU-
668 gastric cancer cells. Cells were treated with or without a GSK-
3b inhibitor LiCl (30 mM) for 48 hours and immunoblot analysis was
performed for pGSK-3b and cyclin D1. b-actin was used as internal
control.
Table 3 The expression of pGSK-3bTyr216 in relation to







Positive 102 (52) 94 (48) 0.002*
Negative 21 (30) 48 (70)
PTEN
Positive 105 (51) 103 (50) 0.006*
Negative 17 (30) 40 (70)
MGMT
Positive 116 (50) 114 (50) < 0.001*
Negative 10 (25) 30 (75)
SMAD4
Positive 117 (49) 121 (51) 0.001*
Negative 7 (19) 30 (81)
KAI1
Positive 109 (52) 99 (48) < 0.001*
Negative 17 (27) 47 (73)
pVHL
Positive 118 (47) 131 (53) 0.091
Negative 7 (28) 18 (72)
FHIT
Positive 62 (48) 68 (52) 0.387
Negative 56 (42) 77 (58)
APC: adenomatous polyposis coli; PTEN: phosphatase and tensin homologue
deleted on chromosome 10; MGMT: O6-methylguanine DNA-
methyltransferase; KAI1: kangai 1; pVHL: von Hippel Lindau protein; FHIT:
fragile histidine triad.
* Considered to be statistically significant (< 0.05)
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with that of cyclin D1. Since the interplay between CDK
inhibitors and cyclin D1-Cdk4 complex is well known,
these findings seem paradoxical. However, our results
are substantiated by a previous report which showed
that treatment of human gastric carcinoma AGS cells
with pterostilbene, an active constituent of blueberries,
increased the p53, p21, p27, and p16 proteins, whereas
the expression of cyclin D1 was not affected [33].
Indeed, a body of evidence accumulated now indicates
that cyclin D1 exhibits CDK-independent properties in
addition to its CDK-dependent function [29]. To clearly
resolve this potential artifact, further molecular studies
are needed.
Previously, it was reported that various tumor-sup-
pressive genes were highly expressed in early-stage gas-
tric carcinomas [26]. In the present study, we examined
the correlation of activated GSK-3b with those tumor
suppressor genes and found that pGSK-3b positively
correlated with the expression of p53, APC (P = 0.002),
PTEN (P = 0.006), MGMT (P < 0.001), Smad4
(P = 0.001), or KAI1 (P < 0.002), which were shown to
be correlated with good gastric carcinoma prognosis and
may act as negative regulators throughout the prolifera-
tion or progression of cancer cells [26]. In contrast,
correlation was not shown between the expression of
pGSK-3b and that of pVHL (P = 0.091) or FHIT
(P = 0.387). The cellular mechanism in relation to the
association between activated GSK-3 and tumor sup-
pressive genes in early-stage gastric cancer remains to
be elucidated.
Conclusions
Our results demonstrated that activated GSK-3b was
more frequent in the early-stage gastric carcinoma, was
negatively associated with nodal status, and was posi-
tively associated with better prognosis. In addition, it
positively correlated with several tumor suppressor
genes, including CDK inhibitors. Although further inves-
tigations are needed to clarify the molecular mechan-
isms involved in GSK-3b activation, the present findings
suggest that GSK-3b activation plays an important role
probably via inhibition of cell cycle progression, and is a
candidate prognostic biomarker in gastric carcinoma.
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